Whalesbook
Poultry Segment Drives Profit Surge
Hester Biosciences concluded FY26 with a powerful fourth quarter, reporting consolidated revenue of ₹100.11 crore, a 22% increase from ₹81.93 crore in the prior year. This growth translated into exceptional net profit expansion, soaring 974% to ₹16.55 crore from ₹1.54 crore a year earlier. The quarter's EBITDA climbed 167% to ₹36.10 crore, driving EBITDA margins to a strong 36%, a significant jump from 17% in Q4 FY25. Gross profit margins also improved by 6 percentage points year-over-year. For the full fiscal year, revenue grew 7% to ₹332.60 crore, while net profit climbed 99% to ₹57.48 crore. The annual EBITDA margin expanded by 10 percentage points to 32%. The company also announced the capitalization of its BSL-3 facility as part of capacity expansion efforts and secured marketing and manufacturing licenses for its H9N2 Avian Influenza vaccine. The strong financial performance, combined with the board's recommended dividend of ₹11 per share, led to an immediate market reaction, with Hester Biosciences shares rising 4.82% to ₹1,824 on the NSE following the results.
Animal Health Division Faces Decline
While the poultry segment showed strong momentum, Hester Biosciences' Animal Healthcare Division presented a contrasting trend. In Q4 FY26, this division reported a 6% year-over-year revenue decline to ₹28.64 crore from ₹30.54 crore. This dip was attributed to ongoing challenges, including delays in government immunization programs and uneven market demand. For the full fiscal year, this division's revenue fell 32% to ₹81.83 crore from ₹119.88 crore in FY25. This ongoing weakness in animal health raises questions about the company's revenue diversification and its reliance on poultry for growth, as the animal health segment's performance affected overall standalone results.
Valuation and Market Standing
With a market capitalization around ₹1,480 crore, Hester Biosciences trades at a P/E ratio between 35-40x. This valuation seems reasonable given its margin expansion and recovery, though recent analyst coverage is limited, making direct peer valuation challenging. Globally, Zoetis Inc. is the leader in the animal health industry with over $9.2 billion in 2024 revenue, holding about 20% of the global market share. Hester Biosciences holds a significant ~10% share in the Indian animal health market but is dominant in specific areas, as the largest global manufacturer of PPR vaccines (~75% market share) and the second-largest poultry vaccine producer in India (~35% market share). Competitors like Merck Animal Health and Virbac also hold considerable stakes in the Indian market. The company aims to strengthen its biologicals portfolio and expand into export markets like Africa to counter competition and diversify revenue.
Favorable Sector Trends and Support
The Indian animal health market is expected to grow significantly, with forecasts suggesting a compound annual growth rate (CAGR) between 7.11% and 13.9% over the next decade, potentially reaching over INR 171 billion by 2034. This growth is strongly supported by government initiatives, including investments in veterinary infrastructure and programs like the National Animal Disease Control Programme. The Union Budget 2026 also continued this support with an allocation of ₹3,880 crore for livestock health and disease control. These policies, focused on disease prevention and vaccination, create a positive environment for companies like Hester Biosciences, especially for its vaccine segment. The recent approval for its H9N2 Avian Influenza vaccine fits well with these national health goals.
Stock's Reaction to Earnings
Hester Biosciences' stock has historically shown volatile reactions to earnings announcements. Past reports have led to price movements ranging from significant increases (e.g., +8.67% in August 2025) to notable decreases (e.g., -9.84% in August 2024). This suggests the market often balances strong results against factors like performance sustainability and overall company trends.
Potential Risks
Despite the strong headline figures, several potential risks warrant attention. The sharp margin expansion seen in Q4 FY26 might be difficult to sustain if the product mix changes or input costs increase. The continued decline in the Animal Healthcare Division is a significant concern, suggesting structural challenges or competitive pressures that could hide underlying weaknesses in the company's diversified strategy. While the reliance on the poultry sector is currently a strength, it could become a vulnerability if avian diseases or market shifts occur. Limited recent analyst coverage and a lack of clear forward-looking guidance make it hard to gauge investor confidence in sustained growth. Competitors like Zoetis, operating at a much larger scale with diversified portfolios and substantial R&D, pose a significant competitive threat. Hester's mixed stock reactions after earnings suggest investor skepticism about the durability of its financial improvements, especially given the differing segment performance.
Outlook and Strategy
Management plans to strengthen its biologicals portfolio for both poultry and animal healthcare, aiming to boost domestic and international market penetration. Efforts are underway to diversify its portfolio, reduce reliance on institutional business, and expand its presence in Africa and other export markets. The capitalization of the BSL-3 facility and the new H9N2 vaccine license are key steps to enhance its offerings and capacity. However, success hinges on revitalizing the Animal Healthcare Division and sustaining current profitability in the poultry segment.